insights_auto
Outlook: 34.0% bullish·11.3% bearish
Go to analysischevron_right
BMY:NYSE
Bristol-Myers Squibb Co
$59.75
arrow_downward
-1.35%(-0.82) 1D
$60.19
arrow_upward
+0.73% (+0.44)bedtimeAfter hours
Closed: Oct 16, 4:00:07 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMY...
Open
$61.10
High
$61.43
Low
$59.54
Mkt. cap
122.05B
Avg. vol.
12.53M
Volume
13.77M
Dividend
4.22%
Quarterly dividend
$0.63
Ex-dividend date
Oct 2, 2026
P/E ratio
13.16
52-wk high
$68.64
52-wk low
$42.52
EPS
$4.54
Beta
0.19
Shares outstanding
2.04B
No. of employees
32K
Open
$61.10
High
$61.43
Low
$59.54
Mkt. cap
122.05B
Avg. vol.
12.53M
Volume
13.77M
Dividend
4.22%
Quarterly dividend
$0.63
Ex-dividend date
Oct 2, 2026
P/E ratio
13.16
52-wk high
$68.64
52-wk low
$42.52
EPS
$4.54
Beta
0.19
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
ad-hoc-news.de
·
2 hours ago
Bristol Myers Squibb reports ACTION-1 results. Bristol Myers Squibb stock trades at EUR 53.39
MarketBeat
·
9 hours ago
Birch Hill Investment Advisors LLC Acquires 160,411 Shares of Bristol Myers Squibb Company $BMY
The Motley Fool
·
1 day ago
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Seeking Alpha
·
2 days ago
Bristol Myers Squibb: The New Portfolio Is Starting To Carry More Of The Business
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com